Published in J Urol on February 01, 2007
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Recurrence of high-risk bladder cancer: a population-based analysis. Cancer (2013) 1.87
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res (2012) 1.51
MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis (2014) 1.32
Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol (2011) 1.11
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer (2008) 1.06
The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci (2013) 1.05
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer (2012) 1.00
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol (2009) 0.98
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int (2010) 0.97
Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis (2010) 0.94
Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond) (2012) 0.94
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol (2011) 0.93
Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing. PLoS One (2014) 0.93
Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer (2014) 0.91
Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90
Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians. World J Urol (2013) 0.87
Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States. Curr Urol Rep (2014) 0.86
miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit (2014) 0.85
MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One (2015) 0.84
Nestin is an independent predictor of cancer-specific survival after radical cystectomy in patients with urothelial carcinoma of the bladder. PLoS One (2014) 0.83
Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol (2014) 0.83
Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion. Indian J Urol (2012) 0.83
Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther (2008) 0.83
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol (2014) 0.83
Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer Immunol Immunother (2015) 0.81
Robotic radical cystectomy with intracorporeal neobladder: Initial experience and outcomes. Can Urol Assoc J (2015) 0.78
Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy (2016) 0.77
Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics Clin Appl (2014) 0.76
Re: defining optimal therapy for muscle-invasive bladder cancer. Eur Urol (2008) 0.75
In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin. Oncol Lett (2015) 0.75
Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncol Rep (2017) 0.75
Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis. BMC Urol (2016) 0.75
A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells. Int J Mol Sci (2017) 0.75
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer (2016) 0.75
Preliminary experience with radical cystectomy and w-ileal pouch for muscle invasive transitional cell bladder carcinoma. J West Afr Coll Surg (2012) 0.75
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. Can Urol Assoc J (2014) 0.75
[Systemic oncological treatment of bladder cancer]. Wien Med Wochenschr (2007) 0.75
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol (2009) 4.27
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol (2007) 2.20
Where do patients with cancer in Iowa receive radiation therapy? J Oncol Pract (2014) 2.14
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol (2010) 1.97
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol (2007) 1.87
The study of collaborative practice arrangements: where do we go from here? J Clin Oncol (2011) 1.80
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol (2009) 1.80
A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int (2006) 1.79
A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int (2008) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol (2005) 1.71
Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer (2008) 1.70
Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol (2010) 1.70
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol (2005) 1.62
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int (2010) 1.54
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol (2004) 1.50
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol (2010) 1.48
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol (2010) 1.47
Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res (2006) 1.44
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol (2010) 1.42
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer (2009) 1.41
Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol (2010) 1.38
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol (2005) 1.31
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs (2006) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. J Oncol Pract (2014) 1.26
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res (2006) 1.24
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun (2003) 1.19
Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn (2010) 1.19
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int (2009) 1.13
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. Int J Surg Pathol (2002) 1.12
Quality control in transurethral resection of bladder tumours. BJU Int (2008) 1.08
Phase II study of everolimus in metastatic urothelial cancer. BJU Int (2013) 1.07
Recommendations for a global core curriculum in medical oncology. J Clin Oncol (2004) 1.06
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol (2011) 1.05
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol (2003) 1.03
Laparoscopic partial nephrectomy for central tumors: analysis of perioperative outcomes and complications. J Urol (2008) 1.03
Kidney spheroids recapitulate tubular organoids leading to enhanced tubulogenic potency of human kidney-derived cells. Tissue Eng Part A (2011) 1.02
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? J Clin Oncol (2011) 1.02
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology (2007) 1.02
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol (2002) 1.01
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med (2007) 1.01
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst (2013) 1.00
Who does not receive treatment for cancer? J Oncol Pract (2013) 0.99
Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int (2006) 0.98
Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother (2008) 0.98
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol (2013) 0.97
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer (2011) 0.96
Reactivation of NCAM1 defines a subpopulation of human adult kidney epithelial cells with clonogenic and stem/progenitor properties. Am J Pathol (2013) 0.96
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology (2003) 0.96
Access to chemotherapy services by availability of local and visiting oncologists. J Oncol Pract (2014) 0.95
Enhancing the American Society of Clinical Oncology workforce information system with geographic distribution of oncologists and comparison of data sources for the number of practicing oncologists. J Oncol Pract (2014) 0.93
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer (2006) 0.93
Natural history of positive urinary cytology after radical cystectomy. J Urol (2006) 0.93
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol (2007) 0.92
Clinical states model for biomarkers in bladder cancer. Future Oncol (2009) 0.92
Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer (2004) 0.92
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int (2008) 0.91
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol (2004) 0.90
Tracking the workforce: the American Society of Clinical Oncology workforce information system. J Oncol Pract (2013) 0.90
A plea for a uniform surveillance schedule after radical cystectomy. J Urol (2011) 0.90
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res (2008) 0.89
Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol (2005) 0.88
Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int (2013) 0.88
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol (2011) 0.87
Placement of transileal conduit retrograde nephroureteral stents in patients with ureteral obstruction after cystectomy: technique and outcome. AJR Am J Roentgenol (2008) 0.87
The graying of testis cancer patients: what have we learned? J Clin Oncol (2007) 0.86
Optease vena cava filter optimal indwelling time and retrievability. Cardiovasc Intervent Radiol (2010) 0.85
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology (2011) 0.85
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol (2007) 0.85
Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urol Oncol (2010) 0.85
Preoperative serum albumin is associated with mortality and complications after radical cystectomy. BJU Int (2014) 0.85
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol (2006) 0.84
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol (2011) 0.84
Urinary diversion practice patterns among certifying American urologists. J Urol (2012) 0.84
Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. J Urol (2006) 0.83
Elisabeth Pauline Pickett (1918-): opening the door for women in urological oncology. J Urol (2007) 0.83